ERBB2 and breast carcinoma: Another analysis showed that although AR positivity was associated with favorable clinical outcome in the entire early-stage breast cancer, AR positivity was not significantly associated with disease-free survival (DFS) and was significantly associated with a worse OS rate in the HER2 positive breast cancer subgroup [16].